Positron emission tomography molecular imaging for drug development.

Area of Science:

• Pharmacology
• Molecular Imaging
• Drug Development

Background:

• Precision pharmacology aims to optimize drug development by understanding molecular interactions in vivo.
• Human molecular imaging, particularly Positron Emission Tomography (PET), offers novel insights into drug behavior within the body.

Purpose of the Study:

• To highlight the utility of in vivo molecular imaging, specifically PET, in advancing precision pharmacology and drug development.
• To demonstrate how PET can address key questions regarding drug biodistribution, target occupancy, and pharmacodynamics.

Main Methods:

• Utilizing PET with positron-emitting radioisotopes for biodistribution studies of new chemical entities.
• Employing competition studies with specific radioligands to assess drug-target engagement and plasma concentration relationships.
• Measuring biological process rates and pharmacodynamic changes using tailored radiotracers and tissue marker-specific radioligands.
• Integrating PET with Magnetic Resonance Imaging (MRI) to correlate molecular events with anatomical and physiological changes.

Main Results:

• PET enables assessment of whether drugs reach target tissues in sufficient amounts.
• PET allows direct measurement of the relationship between drug concentration and target occupancy.
• PET can quantify biological process rates and provide pharmacodynamic information.
• Combined PET-MRI visualizes molecular interactions within anatomical and physiological contexts.

Conclusions:

• Molecular imaging with PET is a powerful tool for precision pharmacology, improving early drug development decision-making.
• Strategic application of PET can enhance R&D investment returns by reducing drug attrition rates.
• Integrating translational molecular imaging early in drug development is crucial for personalized medicine and maximizing drug value.